Literature DB >> 32337634

Circulating interleukin-23 levels in ankylosing spondylitis and their correlation with disease activity : A meta-analysis.

Y H Lee1,2, G G Song3.   

Abstract

OBJECTIVE: To systematically investigate the relationship between circulating interleukin-23 (IL‑23) levels and ankylosing spondylitis (AS) and establish a correlation between these hematological indices and AS activity/severity.
METHODS: We searched the Medline, Embase, and Cochrane databases; performed a meta-analysis comparing serum/plasma IL‑23 levels in patients with AS to those of controls; and examined the correlation coefficients between serum/plasma IL‑23 levels and AS activity.
RESULTS: Ten studies including 1724 patients with AS and 1589 controls were included in this meta-analysis. This meta-analysis showed that circulating IL‑23 levels were significantly higher in the AS than in the control group (standardized mean difference [SMD] 1.479; 95% confidence interval [CI] 0.308-2.650; p = 0.013). Stratification by ethnicity showed a significantly increased IL‑23 level in the AS group in an Asian population (SMD 1.551; 95% CI 0.543-2.558; p = 0.003). Stratification by adjustment for age and sex revealed significantly higher IL‑23 levels in the AS adjustment group. Subgroup analysis of sample size showed a significantly higher IL‑23 level for a small (n < 150) sample number in the AS group. Meta-analysis of correlation coefficients revealed that the IL‑23 level was positively associated with the Bath Ankylosing Spondylitis Metrology Index (BASMI; correlation coefficient 0.464; 95% CI 0.027-0.752; p = 0.038), erythrocyte sedimentation rate (ESR; correlation coefficient 0.258; 95% CI 0.076-0.422; p = 0.006), and C‑reactive protein (CRP; correlation coefficient 0.291; 95% CI 0.053-0.498; p = 0.017).
CONCLUSION: This meta-analysis demonstrated that the circulating IL‑23 level is significantly higher in patients with AS, and a significant positive correlation exists between the circulating IL‑23 level and BASMI, ESR, and CRP.
© 2020. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Ankylosing spondylitis; Inflammation; Interleukin-23; Relationship

Mesh:

Substances:

Year:  2021        PMID: 32337634     DOI: 10.1007/s00393-020-00804-4

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  7 in total

Review 1.  Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review.

Authors:  J Ruof; G Stucki
Journal:  J Rheumatol       Date:  1999-04       Impact factor: 4.666

Review 2.  Genetics of ankylosing spondylitis.

Authors:  M A Brown; B P Wordsworth; J D Reveille
Journal:  Clin Exp Rheumatol       Date:  2002 Nov-Dec       Impact factor: 4.473

3.  Biological and clinical markers of disease activity in ankylosing spondylitis.

Authors:  María Carmen Muñoz-Villanueva; Elisa Muñoz-Gomariz; Alejandro Escudero-Contreras; Verónica Pèrez-Guijo; Eduardo Collantes-Estévez
Journal:  J Rheumatol       Date:  2003-12       Impact factor: 4.666

4.  Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index.

Authors:  T R Jenkinson; P A Mallorie; H C Whitelock; L G Kennedy; S L Garrett; A Calin
Journal:  J Rheumatol       Date:  1994-09       Impact factor: 4.666

5.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Authors:  A Calin; S Garrett; H Whitelock; L G Kennedy; J O'Hea; P Mallorie; T Jenkinson
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

6.  A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.

Authors:  S Garrett; T Jenkinson; L G Kennedy; H Whitelock; P Gaisford; A Calin
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

7.  Elevated serum interleukin-23 levels in ankylosing spondylitis patients and the relationship with disease activity.

Authors:  Mahir Ugur; Nurcan Kilic Baygutalp; Meltem Alkan Melikoglu; Fatih Baygutalp; Elif Umay Altas; Buminhan Seferoglu
Journal:  Nagoya J Med Sci       Date:  2015-11       Impact factor: 1.131

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.